Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | Restarting the apoptotic pathway in myeloma cells

Many tumor cells are able to evade apoptosis, with the potential to survive in the body indefinitely. Here, Shaji Kumar, MD, of the Mayo Clinic, Rochester, MN, explains some of the mutations that allow this to happen and highlights the need for therapies that target these anti-apoptotic pathways. Dr Kumar mentions clinical trials that are investigating the use of venetoclax to re-initiate apoptosis in multiple myeloma (MM). This interview was recorded at 23rd Congress of the European Hematological Association (EHA) 2018, held in Stockholm, Sweden.